Here are the key details: Start date: July 1, 2026 End date: December 31, 2027 (unless extended by Congress) Eligible medications: FDA-approved anti-obesity medications, including Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) Patient cost: Flat $50 per month copay Deductible: Waived - the Part D deductible does not apply to medications obtained through this program Prior authorization: Required by most Part D plans, but criteria are standardized under the program The bridge structure is important to understand
All this time, I thought stopping my vices would be enough to allow me to enjoy the quality of life I witnessed in others
Human ChaC1 has potential ability to promote inflammation (129)
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates a second hormone pathway in addition to GLP-1
74% female) underwent standardized LSG and was followed for five years with annual measurements of weight, BMI, %TWL, %EWL, GLP-1 and GIP
Concentration is what converts volume into mass
